Forward Looking Statements
The information provided on this website includes forward-looking information and forward-looking statements (collectively, “forward-looking statements” within the meaning of applicable securities laws, including within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995) related to Sorrento Therapeutics, Inc. (“Sorrento”). Forward-looking statements reflect Sorrento management’s expectations and beliefs regarding future events and may also reflect Sorrento management’s plans, goals, objectives and missions. These forward-looking statements do not relate strictly to historical or current facts and they may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. These statements relate to, among other things, Sorrento management’s expectations regarding plans, objectives, strategies, future operating or financial performance, business plans and prospects, and expectations regarding clinical trials, development timelines, discussions with regulatory authorities, development programs, development candidates and investigational medicines under development by Sorrento and by Sorrento’s strategic partners. The forward-looking statements on this website are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Sorrento’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact of general economic conditions, economic conditions in the biopharmaceutical industry, changes in the regulatory environment, stock market volatility, fluctuations in costs, our ability to develop and protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, reliance on third parties and/or collaborative agreements for successful development and commercialization of our products, changes in the competitive landscape, changes in the standard of care for the various indications in which Sorrento is involved, and other risks detailed in Sorrento’s annual report on Form 10-K, as well as other subsequent filings made from time to time with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These risks and uncertainties could cause future results, performance or achievements to differ materially from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing of enrollment or completion of clinical trials, the results of clinical trials, the timing and effects of regulatory action, the relative success or the lack of success in developing and gaining regulatory approval of Sorrento’s product candidates, the success, efficacy or safety of any of Sorrento’s product candidates, the ability to scale up, formulate and manufacture sufficient good manufacturing practices, clinical or commercialization quantities of Sorrento’s product candidates, and the relative success or the lack of success in the market acceptance of any of Sorrento’s product candidates. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.
On this website, Sorrento management may refer to results, projections or performance measures that are not prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) as reported in the company’s SEC filings. These results, projections or performance measures are non-GAAP measures and are not intended to replace or substitute for results measured under GAAP and are supplemental to GAAP reported results.
These forward-looking statements speak only as of the date they are first made or updated on this website, and Sorrento hereby disclaims any intention, duty, obligation or undertaking to revise or update forward-looking statements contained on this website.